| 47221-7 |
Cholesterol.in HDL 1+2 |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol in HDL 1+2 [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
47221-7 |
|
|
|
|
Observation |
|
|
|
0 |
HDL1+2c SerPl-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; HDL1+2c; HDLc; HDL-C; Heart Disease; High density lipoprotein cholesterols; i; II; Level; Lipid; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; TCHHDL |
2.34 |
2.19 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 47222-5 |
Trisomy 21 risk based on maternal age + Alpha-1-Fetoprotein + Choriogonadotropin + Estriol.unconjugated |
Likelihood |
^Fetus |
Pt |
Qn |
|
|
ACTIVE |
Trisomy 21 risk based on maternal age+Alpha-1-Fetoprotein+Choriogonadotropin+Estriol.unconjugated [Likelihood] in Fetus |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
47222-5 |
|
|
|
|
Observation |
|
|
|
0 |
Ts 21risk-age+AFP+HCG+uE3 Fetus |
|
|
|
N |
|
A1; AFP; Alfa; Alpha fetoprotein; Alphafetoprotein; CG; Chemistry; Choriogonadotropins total; Chorionic gonadotropin; Down syndrome; Downs; Down's syndrome; ds; E3; Estriol free; Fetal; Feto; Gyn; Gynecology; HCG; Human chorionic gonadotropin; i; OB; ObGyn; Obstetrics; Point in time; QNT; Quan; Quant; Quantitative; Random; Risk; Ts; Ts 21 risk; Ts 21risk-age; Ts 21risk-age+AFP+HCG+uE3; Tumor marker; u Estriol; uE3; Uncnj; Unconj; Unconjug; Unconjugat |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 47223-3 |
Fetal trisomy 18 risk |
Likelihood |
^Fetus |
Pt |
Qn |
Based on maternal age |
|
ACTIVE |
Fetal Trisomy 18 risk [Likelihood] Based on maternal age |
|
MIN |
DefinitionDescription |
|
|
Risk |
|
|
|
|
|
|
CHEM |
|
47223-3 |
|
Based on maternal age |
|
|
Observation |
|
|
|
0 |
Fet Ts 18 risk from Mat age |
|
|
|
N |
|
Chemistry; Edward syndrome; Fetal; from Mat age; Gyn; Gynecology; OB; ObGyn; Obstetrics; Point in time; QNT; Quan; Quant; Quantitative; Random; Risk; T18 risk; Ts; Ts 18 risk |
2.73 |
2.19 |
|
|
|
|
|
|
|
{risk} |
|
|
Removed "based on maternal age" from Component and added Method; Added "Fetal" to Component for consistency across terms that represent fetal risk and vary by System |
0 |
| 47224-1 |
In vitro fertilization pregnancy |
PrThr |
^Patient |
Pt |
Ord |
|
|
ACTIVE |
In vitro fertilization pregnancy |
|
MIN |
DefinitionDescription |
|
|
|
Yes/No |
|
|
|
|
|
CLIN |
|
47224-1 |
|
|
|
|
Observation |
|
|
|
0 |
IVF pregnancy |
|
|
|
N |
|
CLIN; Gestation; Gestations; Gravida; Gyn; Gynecology; IVF pregnancy; OB; ObGyn; Obstetrics; Ordinal; Point in time; PR; Pregnancies; QL; Qual; Qualitative; Random; Screen |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47225-8 |
Bilirubin |
Imp |
Amnio fld |
Pt |
Nom |
|
|
ACTIVE |
Bilirubin.total [Interpretation] in Amniotic fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
47225-8 |
|
|
|
|
Observation |
|
|
|
0 |
Bilirub Amn-Imp |
|
|
|
N |
|
AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Bili; Bilirubins; Billirubin; Chemistry; Gyn; Gynecology; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; OB; ObGyn; Obstetrics; Point in time; Random; TBIL |
2.5 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 47226-6 |
Fetal lung maturity |
Imp |
Amnio fld |
Pt |
Nom |
|
|
ACTIVE |
Fetal lung maturity [Interpretation] in Amniotic fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
47226-6 |
|
|
|
|
Observation |
|
|
|
0 |
FLM Amn-Imp |
|
|
|
N |
|
AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Chemistry; Fetal lung maturity; FLM; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 47227-4 |
Blood.dried |
PrThr |
Calculus |
Pt |
Ord |
|
|
ACTIVE |
Blood.dried [Presence] of Stone Qualitative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
47227-4 |
|
|
|
|
Observation |
|
|
|
0 |
Bld.dried Stone Ql |
|
|
|
N |
|
Bld.dried; Calc; Calculi; Gastro; Gastroenterology; GI; Kidney; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; SPEC; Stn; Stone; Stones |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47228-2 |
Cholesterol.non HDL/Cholesterol.total |
MRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol non HDL/Cholesterol.total [Mass Ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
47228-2 |
|
|
|
|
Observation |
|
|
|
0 |
NonHDLc SerPl |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; LDL + IDL + VLDL; Lipid; Mass concentration ratio; Mass ratio; MCRto; NonHDLc; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; TC; Tot; Totl |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 47229-0 |
Herpes simplex virus Ag |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Herpes simplex virus Ag [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47229-0 |
|
|
|
|
Both |
|
|
|
0 |
HSV Ag CSF Ql |
|
|
|
N |
|
Antigen; Antigens; Cerebral spinal fluid; Cerebrospinal Fl; Herp splx; HSV; ID; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4723-3 |
HLA-A25(10) |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-A25(10) [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4723-3 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A25(10) Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47230-8 |
Herpes simplex virus glycoprotein G Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Herpes simplex virus glycoprotein G IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47230-8 |
|
|
|
|
Both |
|
|
|
0 |
HSV gp G IgG Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; gG; Glycoprot; Glycoproteins; GP; Herp splx; HSV; HSV gp G; HSV gp G Ab; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47231-6 |
IgM Ab |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
IgM Ab [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
47231-6 |
|
|
|
|
Both |
|
|
|
0 |
IgM Ab SerPl Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Chemistry; Immune globulin M; Immunoglobulin M; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47232-4 |
Influenza virus A Ab^1st specimen |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Influenza virus A Ab [Presence] in Serum --1st specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47232-4 |
|
|
|
|
Both |
|
|
|
0 |
FLUAV Ab sp1 Ser Ql |
|
|
|
N |
|
ABS; Aby; Acute specimen; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Avian influenza; Bird flu; First; FLUA; FLUAV; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; Microbiology; Ordinal; Point in time; PR; Pre immunization; QL; Qual; Qualitative; Random; Screen; Serum; sp1; Spec; SR |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47233-2 |
Influenza virus A Ab^2nd specimen |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Influenza virus A Ab [Presence] in Serum --2nd specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47233-2 |
|
|
|
|
Both |
|
|
|
0 |
FLUAV Ab sp2 Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Avian influenza; Bird flu; Convalescent; FLUA; FLUAV; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; Microbiology; Ordinal; Point in time; Post immunization; PR; QL; Qual; Qualitative; Random; Screen; Second; Serum; sp2; Spec; SR |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47234-0 |
Chlamydia trachomatis Ag |
PrThr |
Body fld |
Pt |
Ord |
|
|
ACTIVE |
Chlamydia trachomatis Ag [Presence] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47234-0 |
|
|
|
|
Both |
|
|
|
0 |
C trach Ag Fld Ql |
|
|
|
N |
|
Antigen; Antigens; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; Fl; Fld; FLU; Fluid; ID; Infectious Disease; InfectiousDisease; LGV; Lymphogranuloma venereum; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Trachoma |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47235-7 |
Reagin Ab |
Titr |
XXX |
Pt |
SemiQn |
VDRL |
|
ACTIVE |
Reagin Ab [Titer] in Specimen by VDRL |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
47235-7 |
|
VDRL |
|
|
Both |
|
|
|
0 |
VDRL Spec-Titr |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Microscopic flocculation; Misc; Miscellaneous; Neurosyphilis; Other; Point in time; Random; SmQn; Spec; Syphilis; Titer; Titered; Titre; To be specified in another part of the message; Treponema; Ttr; Unspecified; Venereal Disease Research Laboratory |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 47236-5 |
Treponema pallidum Ab.IgG+IgM |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Treponema pallidum IgG+IgM Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47236-5 |
|
IA |
|
|
Both |
|
|
|
0 |
T pallidum IgG+IgM Ser Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin G; Immune globulin M; Immunoglobulin G; Immunoglobulin M; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS; Syphilis; T pallidum; Treponemal |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47237-3 |
Treponema pallidum Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Treponema pallidum IgM Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47237-3 |
|
IA |
|
|
Both |
|
|
|
0 |
T pallidum IgM Ser Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS; Syphilis; T pallidum; Treponemal |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47238-1 |
Treponema pallidum Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Treponema pallidum IgG Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
47238-1 |
|
IA |
|
|
Both |
|
|
|
0 |
T pallidum IgG Ser Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS; Syphilis; T pallidum; Treponemal; UniversalLabOrders |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47239-9 |
Reason for stopping HIV Rx |
Type |
^Patient |
Pt |
Nom |
Reported |
|
ACTIVE |
Reason for stopping HIV treatment |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47239-9 |
|
Reported |
|
|
Observation |
|
|
|
0 |
Reason for stopping HIV Rx |
|
|
|
N |
|
AIDS; Anti-retroviral therapy; ART; Human immunodeficiency virus; ID; Infectious Disease; InfectiousDisease; Nominal; Point in time; Random; Treatment; Typ |
2.67 |
2.22 |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 4724-1 |
HLA-A26(10) |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A26(10) [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4724-1 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A26(10) Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 47240-7 |
Date determined medically eligible to start HIV Rx |
Date |
^Patient |
Pt |
Qn |
Reported |
|
ACTIVE |
Date determined medically eligible to start HIV treatment |
|
MIN |
DefinitionDescription |
|
|
MMDDYY |
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47240-7 |
|
Reported |
|
|
Observation |
|
|
|
0 |
Date eligible to start HIV Rx |
|
|
|
N |
|
AIDS; Anti-retroviral therapy; Date eligible to start HIV Rx; Human immunodeficiency virus; ID; Infectious Disease; InfectiousDisease; Point in time; QNT; Quan; Quant; Quantitative; Random; Started; Treatment |
2.67 |
2.22 |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 47241-5 |
Date determined medically eligible and ready to start HIV Rx |
Date |
^Patient |
Pt |
Qn |
Reported |
|
ACTIVE |
Date determined medically eligible and ready to start HIV treatment |
|
MIN |
DefinitionDescription |
|
|
MMDDYY |
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47241-5 |
|
Reported |
|
|
Observation |
|
|
|
0 |
Date eligible & ready to start HIV Rx |
|
|
|
N |
|
AIDS; Anti-retroviral therapy; Date eligible & ready to start HIV Rx; Human immunodeficiency virus; ID; Infectious Disease; InfectiousDisease; Point in time; QNT; Quan; Quant; Quantitative; Random; Started; Treatment |
2.67 |
2.22 |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 47242-3 |
Medication or other side effects associated with HIV Rx |
Type |
^Patient |
Pt |
Nom |
Reported |
|
ACTIVE |
Medication or other side effects associated with HIV treatment |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47242-3 |
|
Reported |
|
|
Observation |
|
|
|
0 |
Med/other side effects assoc with HIV Rx |
|
|
|
N |
|
AIDS; Anti-retroviral therapy; ART; Assoc; Human immunodeficiency virus; ID; Infectious Disease; InfectiousDisease; Med/other side effects assoc with HIV Rx; Nominal; Othr; Point in time; Random; Treatment; Typ |
2.67 |
2.22 |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
| 47243-1 |
Severity of side effect to HIV Rx |
Type |
^Patient |
Pt |
Nom |
Reported |
|
ACTIVE |
Severity of side effect to HIV treatment |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
ART |
|
47243-1 |
|
Reported |
|
|
Observation |
|
|
|
0 |
Severity of side effect to HIV Rx |
|
|
|
N |
|
AIDS; Anti-retroviral therapy; ART; Human immunodeficiency virus; ID; Infectious Disease; InfectiousDisease; Nominal; Point in time; Random; Treatment; Typ |
2.67 |
2.22 |
|
|
|
|
Copyright �© 2006 World Health Organization. Used with permission. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. |
|
|
|
|
|
|
0 |
